Hybio Pharmaceutical

Hybio operates as a pioneering technology company specializing in the research and development as well as the production of a wide range of peptide goods. Established in 1998, we have evolved into a prominent peptide pharmaceutical firm and the first to go public in China (2011, stock code 300199). Our offerings encompass a comprehensive selection of peptide products (Active Pharmaceutical Ingredients & Finished Dosage Forms) and solutions (Contract Research Organization & Contract Development and Manufacturing Organization). The primary market for our peptide Finished Dosage Forms is within China.

Products & Services

Bivalirudin

Bivalirudin Non Sterile Bulk Drug Substance

Carbetocin

Country

People's Republic of China

Show site details

Audit report available

Hybio Pharmaceutical (Wuhan) Co., Ltd.

Country

People's Republic of China

City

Wuhan

Carbetocin

Cetrorelix Acetate

Sites